reports
Columbus – Weekly report on share buyback
Columbus – Weekly report on share buyback Company announcement no. 14/2025 Transactions in the period 28 July 2025 to 1 August 2025On 30 June 2025, Columbus A/S announced a share buyback programme under which the company will repurchase shares for up to DKK 16m during the period from 30 June 2025 to 11 March 2026, both dates included, as outlined in company announcement no. 8/2025. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and the Commissi...
Columbus – Weekly report on share buyback
Columbus – Weekly report on share buyback Company announcement no. 13/2025 Transactions in the period 21 July 2025 to 25 July 2025On 30 June 2025, Columbus A/S announced a share buyback programme under which the company will repurchase shares for up to DKK 16m during the period from 30 June 2025 to 11 March 2026, both dates included, as outlined in company announcement no. 8/2025. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and the Commission ...
Columbus - Weekly report on share buyback
Columbus - Weekly report on share buyback Company announcement no.12/2025 July 21st, 2025Columbus A/S share buyback programme Company announcement Columbus – Weekly report on share buyback Transactions in the period 14 July 2025 to 18 July 2025On 30 June 2025, Columbus A/S announced a share buyback programme under which the company will repurchase shares for up to DKK 16m during the period from 30 June 2025 to 11 March 2026, both dates included, as outlined in company announcement no. 8/2025. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 ...
- Maria Vara
BONESUPPORT: 2025 Trim; Spine optionality kicks in
Following Q2 earnings, we revisited our expectations across all business segments, leading to a 9% 2025E sales cut, majorly driven by FX headwinds on US sales, while country-specific policies in EUROW led to softer-than-expected H1 growth. Our long-term thesis remains unchanged, and we see improvin
Adjusted financial guidance for 2025
Adjusted financial guidance for 2025 Release no. 11/2025 July 16th, 2025Columbus adjusts financial guidance for 2025 Company announcement Adjusted financial guidance for 2025 Columbus A/S announces adjustment of the full-year guidance for 2025. Overall, we are facing a challenging macro-economic environment that negatively impacts our customers’ decision-making in major IT projects, resulting in postponement of projects and extended sales processes. Due to the expected continued marked uncertainty, Columbus adjusts the full-year guidance for 2025. Revenue guidance is adjusted ...
- ABGSC Healthcare Research
- Sten Gustafsson
- Maria Vara
BONESUPPORT: Q2 US momentum in line; softer EU and FX weigh on EBIT
BONESUPPORT reported Q2 2025 net sales of SEK 284.4m, slightly below CSS SEK 291m (Stifel est. SEK 299m), with the deviation primarily due to a softer-than-expected European performance. Growth was led by the US, which grew 36% YoY reported (49% CER), though it fell -2%, and -4% vs CSS and our expe
- ABGSC Healthcare Research
- Sten Gustafsson
Columbus – Weekly report on share buyback
Columbus – Weekly report on share buyback Company announcement no. 10/2025 Transactions in the period 7 July 2025 to 11 July 2025On 30 June 2025, Columbus A/S announced a share buyback programme under which the company will repurchase shares for up to DKK 16m during the period from 30 June 2025 to 11 March 2026, both dates included, as outlined in company announcement no. 8/2025. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and the Commission...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Columbus – Weekly report on share buyback
Columbus – Weekly report on share buyback Company announcement no. 9/2025 Transactions in the period 30 June 2025 to 4 July 2025On 30 June 2025, Columbus A/S announced a share buyback programme under which the company will repurchase shares for up to DKK 16m during the period from 30 June 2025 to 11 March 2026, both dates included, as outlined in company announcement no. 8/2025. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and the Commission De...
Columbus – launch of share buyback programme under the “Safe Harbour” ...
Columbus – launch of share buyback programme under the “Safe Harbour” Regulation Company announcement no. 8/2025 The Board of Directors in Columbus A/S has decided to initiate a share buyback programme for a total amount of up to DKK 16m. The authority to buy back shares was granted at the company’s Annual General Meeting held on 29 April 2025, allowing for share buyback of up to 10% of the share capital in the period until 29 October 2026 (18 months from the date of the General Meeting). PurposeThe purpose of the share buyback programme is to reduce the Company’s share capital and to hed...
- ABGSC Healthcare Research
- Sten Gustafsson
- ABGSC Healthcare Research
- Sten Gustafsson
Arjo AB: 1 director
A director at Arjo AB bought 100,000 shares at 32.750SEK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Bonesupport Holding AB: 1 director
A director at Bonesupport Holding AB bought 2,000 shares at 273.000SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Notification of transactions in Columbus A/S shares and related securi...
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them Company announcement no. 7/2025 In accordance with Article 19 (3) of the Market Abuse Regulation, Columbus A/S is required to disclose information regarding trading in Columbus A/S shares and/or related securities by persons discharging managerial responsibilities in Columbus A/S and/or persons closely associated with them. Please see the attached documents for transaction details reported to Columbus. Ib Kunøe ...
Columbus has completed strategic review
Columbus has completed strategic review Company announcement no. 6/2025 As announced in company announcement no. 1/2025 of January 17th, 2025, Columbus has conducted a strategic review to evaluate possible changes in the ownership structure, mergers or other consolidation. During the period of the review, the global financial markets have been considerably affected by increased uncertainty, leading to a significant slowdown in M&A transactions. The Board of Directors has concluded that the obtainable premium associated with a change of ownership is at an unsatisfactory level, hence the Boa...
Columbus Interim Report Q1 2025
Columbus Interim Report Q1 2025 Company announcement no. 5/2025 Solid operational performance in Q1 2025 Columbus delivered a solid start to 2025, driven by improved earnings, confirming the robustness of the strategy and business model. Despite a slight decline in revenue of 2%, a 32% improvement in EBITDA was achieved, significantly strengthening profitability and increasing the EBITDA margin to 10.7% compared to 7.9% in Q1 2024, adjusted for the extraordinary gain of DKK 20m from the M3CS legal case. Overall, a satisfactory start to the year. “Despite global uncertainty, Q1 2025 refle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.